2266. Deputy Pádraig O'Sullivan asked the Minister for Health the number of patients receiving standard oral nutritional supplements reimbursed under the community drug schemes, broken down by those receiving first-line products on List A and those receiving non first-line products on List B, in tabular form; and if she will make a statement on the matter. [43512/26]
Topics / Medicinal Products
A subject heading for parliamentary questionsMedicinal Products
1,233 questions from 132 TDs, between 22 January 2025 and 22 October 2026.
1,233
questions
1,229 written, 4 oral
132
TDs have asked
11
parties and groups
Independents counted together
4
departments asked
Questions per month
The record holds no questions for August, when the Dáil does not sit.
Jan 2025Oct 2026
Show as a table
| Month | Questions |
|---|---|
| January 2025 | 17 |
| February 2025 | 66 |
| March 2025 | 28 |
| April 2025 | 35 |
| May 2025 | 43 |
| June 2025 | 58 |
| July 2025 | 56 |
| August 2025 | 0 |
| September 2025 | 36 |
| October 2025 | 38 |
| November 2025 | 58 |
| December 2025 | 27 |
| January 2026 | 18 |
| February 2026 | 70 |
| March 2026 | 142 |
| April 2026 | 87 |
| May 2026 | 156 |
| June 2026 | 127 |
| July 2026 | 82 |
| August 2026 | 0 |
| September 2026 | 62 |
| October 2026 | 27 |
Who asks, by party
The party each TD belonged to on the day, in alphabetical order. Parties differ a lot in size, and members of the Government answer questions rather than ask them, so this shows who raised it, not how much a party cares about it.
The TDs who asked most
Members of the Government answer questions rather than ask them. Each question counts once.
-
196
-
75
-
43
-
42
-
39
-
26
-
26
-
26
Asked of
Debated under the same heading
Debates whose official heading is exactly these words.
The questions
2267. Deputy Pádraig O'Sullivan asked the Minister for Health if she is satisfied that the categorisation of standard oral nutritional supplements into List A first-line products and List B non first-line products under the Standard Oral Nutritional Supplements First-line Prescribing List for Adults Living in the Community 2019 remains clinically appropriate; whether that list has been reviewed since its introduction…
2268. Deputy Pádraig O'Sullivan asked the Minister for Health the total expenditure by the Health Service Executive on standard oral nutritional supplements reimbursed under the community drug schemes in each year since 2021, in tabular form; and if she will make a statement on the matter. [43514/26]
2269. Deputy Pádraig O'Sullivan asked the Minister for Health the process by which standard oral nutritional supplements are assessed and assigned to List A or List B for reimbursement under the community drug schemes; the criteria applied; the body responsible for making these determinations; and if she will make a statement on the matter. [43515/26]
2270. Deputy Pádraig O'Sullivan asked the Minister for Health the number of prior reimbursement approval applications for List B standard oral nutritional supplements received by the Primary Care Reimbursement Service in each year since 2021; the number approved and refused respectively; the average processing time for such applications; and if she will make a statement on the matter. [43516/26]
2271. Deputy Pádraig O'Sullivan asked the Minister for Health whether she will review the requirement for six-monthly renewal of reimbursement approval for List B standard oral nutritional supplements, given the administrative burden this places on general practitioners, dietitians and hospital clinicians; and if she will make a statement on the matter. [43517/26]
2327. Deputy Ken O'Flynn asked the Minister for Health whether any review, analysis, assessment, briefing, report, business case, internal examination or other evaluation has been undertaken since 1 January 2024 regarding the drivers of variation in reimbursement costs for salbutamol nebule products under the General Medical Services Scheme; if so, to provide the date, author, purpose and principal findings of each s…
2351. Deputy Naoise Ó Muirí asked the Minister for Health the position regarding the availability of the omnipod 5 automated insulin delivery system in Ireland; the status of its approval and reimbursement process; and the timeframe for its expected roll out, in view of its availability in other European countries and the growing demand among Irish diabetes patients for access to advanced insulin delivery technologie…
2359. Deputy Pádraig O'Sullivan asked the Minister for Health the number of applications for new drugs that have been approved for reimbursement in each of the years 2021 to 2025, in tabular form; and if she will make a statement on the matter. [43769/26]
2360. Deputy Pádraig O'Sullivan asked the Minister for Health the number of applications for new drugs that have been refused for reimbursement in each of the years 2021 to 2025, in tabular form; and if she will make a statement on the matter. [43770/26]
2361. Deputy Pádraig O'Sullivan asked the Minister for Health the number of applications for new drugs that are currently under consideration for reimbursement; and if she will make a statement on the matter. [43771/26]
2362. Deputy Pádraig O'Sullivan asked the Minister for Health the drugs that will be considered for reimbursement at the June 2026 meeting of the NCPE drugs group; and if she will make a statement on the matter. [43772/26]
2364. Deputy Pádraig O'Sullivan asked the Minister for Health the status of the progress of givinostat through the drug reimbursement process; and if she will make a statement on the matter. [43774/26]
2365. Deputy Pádraig O'Sullivan asked the Minister for Health if she is satisfied with the NCPEs role within the drug reimbursement process and that appropriate governance and best practice is in situ in its activities; and if she will make a statement on the matter. [43775/26]
2366. Deputy Pádraig O'Sullivan asked the Minister for Health her views on whether it is appropriate for members of the NCPE to be engaging in public commentary while deliberations on certain drugs are currently being undertaken; and if she will make a statement on the matter. [43776/26]
2368. Deputy Pádraig O'Sullivan asked the Minister for Health if the State remains on course to achieve the 180-day review timeline for new medicines and new uses of existing medicines committed to under schedule four of the Framework agreement on the supply and pricing of medicines, given that according to the EFPIA patients W.A.I.T. indicator 2025 survey the average time to access new medicines in Ireland has risen…
2385. Deputy Sean Fleming asked the Minister for Health when a medication will be available for people with medical cards (details supplied); and if she will make a statement on the matter. [43870/26]
2390. Deputy Aengus Ó Snodaigh asked the Minister for Health if she will intervene to ensure that the HSE prioritises a conclusion to the skyclarys reimbursement negotiations, given that it is the only available treatment for this progressive disease, which currently can be classed as having an ‘unmet need’ as outlined in the National Rare Disease Strategy 2025-2030. [43946/26]
2391. Deputy Aengus Ó Snodaigh asked the Minister for Health her views on whether the current delay aligns with the "equitable access" promised in the newly launched National Rare Disease Strategy 2025-2030, given that persons in the Friedreich’s ataxia community in Ireland are being left behind waiting for a decision regarding the skyclarys reimbursement, while patients across Europe gain access to skyclarys (detail…
2398. Deputy Pádraig Rice asked the Minister for Health further to Parliamentary Question No. 566 of 21 April 2026, to provide an update on an application for pricing and reimbursement (details supplied); if the company has submitted a proposal to the HSE’s corporate pharmaceutical unit; if the company has met with the HSE since making an offer; the steps being taken to urgently progress a decision on this applicatio…
2414. Deputy Ken O'Flynn asked the Minister for Health to outline the governance arrangements governing reimbursement rule changes, claim validation criteria, claim rejection criteria and reference pricing decisions within the Primary Care Reimbursement Service, including the decision-making authorities involved, review mechanisms and oversight structures. [44052/26]
2415. Deputy Ken O'Flynn asked the Minister for Health the number of pharmacy reimbursement claims submitted, approved, adjusted, rejected and successfully appealed in each year from 2020 to date, together with the most common reasons recorded for claim rejection or adjustment. [44053/26]
2416. Deputy Ken O'Flynn asked the Minister for Health whether any internal audit, external audit, assurance review, risk assessment or value-for-money review of PCRS reimbursement decision-making processes, claim validation controls, claim rejection procedures or reference pricing arrangements has been completed since 2020 and to provide the dates and findings of such reviews. [44054/26]
57. Deputy Seán Crowe asked the Tánaiste and Minister for Finance his views on the distinction in the VAT rate between oral and injectable medications; if there are plans to include injectable medicines under annex III of the EU VAT Directive in order that the VAT rate can be equalised at 0%; and if he will make a statement on the matter. [40430/26]
212. Deputy Paul Murphy asked the Minister for Health if her attention has been drawn to the case (details supplied); the scrutiny HPRA applied to the necessity and proportionality of the numbers; the alternatives or reductions that were considered; where the animals will come from; how many have already been used; when they will be reflected in official animal-use statistics; and the information that can be disclose…